Posts

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

Hims & Hers is now offering generic semaglutide through its platform to eligible customers in Canada, marking the company’s first international generic GLP-1 offering. The personalized treatment plans, which include medication access plus ongoing care support and lifestyle guidance, start at $149 CAD per month, significantly below the typical cost of branded versions like Ozempic. Generic semaglutide is authorized by Health Canada for Type 2 diabetes and may be prescribed off‑label for weight management by licensed Canadian providers. Hims & Hers does not currently offer treatment services for Type 2 diabetes in Canada and instead focuses on weight‑management programs delivered through its telehealth platform with local Canadian medical providers. Sources: Hims & Hers Expands GLP-1 Offering in Canada with Generic ... Generic Semaglutide Coming to Canada 2026 | Get Notified - Hers HIMS Launches Generic Semaglutide in Canada Hims & Hers Introduces Access to Gene...

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

Amgen’s Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

With Voxzogo under pressure, BioMarin touts trial win in label expansion bid

Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

Pfizer's next-gen pneumonia shot beats Prevnar 20 in infant trial

GHO Capital and CBC Group to merge into world’s largest dedicated healthcare investor

Remepy Reports Strong Clinical Phase IIa Results for Hybridopa, a First‑in‑Class Hybrid Drug for Parkinson’s Disease

Labcorp rolls out AI-powered mobile app to interpret test results

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

BioMarin Suffers Another Blow to Rare Disease Portfolio in Phase 3 Flop